Key points from article :
The company to nominate clinical candidate for dermatology program.
First-in-class and first-in-target approach to inflammatory skin disease.
Validation of selective senolytic approach to cellular senescence biology.
They presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.
Rubedo’s lead compound significantly reduced senescence signatures associated with skin senescent cells.
It also improved skin pathophysiological manifestations, such as chronic desquamation in preclinical animal models of chemotherapy-induced skin fibrosis and dermatitis.
“We’re excited to present for the first time, efficacy data of our lead compound ... further development,” said Ofir Moreno, Senior Vice President.
The data was presented during the 2023 American Academy of Dermatology (AAD) conference week.
